Logo
x

Search

Subscribe Now

 P-II

Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes

Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes

  • November 4, 2024
Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

  • October 30, 2024
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

  • October 30, 2024
EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)

EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)

  • October 29, 2024
Shuttle Pharma Reports the Completion of Clinical Trial Site Enrollment for the P-II Study of Ropidoxuridine for Glioblastoma

Shuttle Pharma Reports the Completion of Clinical Trial Site Enrollment for the P-II Study of Ropidoxuridine for Glioblastoma

  • October 29, 2024
Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD

Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD

  • October 29, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.